Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
24/1/24
Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.
Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.
One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.
Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.
Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.
“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.
Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.
Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.
hTtps://longevity.technology/news/genflow-launches-two-grant-funded-longevity-research-programs/
EXO Biologics will direct the funding towards advancing transformative healthcare initiatives, including the enrolment in EVENEW, the first European Medicines Agency (EMA) authorized clinical trial involving MSC-based exosomes. This EVENEW study is a Phase 1/2 European clinical trial using EXO Biologics’ lead MSC-based exosome candidate EXOB-001. EXO Biologics is initially developing EXOB-001 to prevent Bronchopulmonary Dysplasia (BPD) in preterm newborns.
Directing resources toward enhancing the ExoPulse production platform will enable EXO Biologics to conduct further research into its longer-term aim of loading exosomes with therapeutic molecules such as RNAs, proteins, and chemical drug compounds.
In addition, EXO Biologics will use the funds to reinforce ExoXpert, EXO Biologics’ newly launched subsidiary and one of the first CDMOs specializing in exosomes, leveraging the clinically proven manufacturing platform ExoPulse. By offering access to ExoPulse, ExoXpert can accelerate and de-risk naive and loaded exosome drug development journeys for other companies.
hTtps://www.exobio.be/en/news/14_exo-biologics-secures-up-to-eur-16-million-in-series-a-funding-for-exosome-therapeutic-development-a
Genflow's other partner form the 2.89m Euro grant has just raised a further 16m Euros.and their press release ould appear to be good news for Genflo going forward. Gla ;-)
EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.
The funding will primarily strengthen EXO Biologics’ subsidiary ExoXpert®, the exosome specialist CDMO, support the first EMA approved MSC-derived exosome clinical trial, and fund the ongoing development of the ExoPulseTM platform to produce unmodified and RNA or drug-loaded exosomes.
Liège, Belgium April 24, 2024 – EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, today announces the successful securing of a total of up to EUR 16 million in Series A funding. EXO Biologics will use the funds to support its ongoing and future clinical trials. It will also use funds to continue its manufacturing expansion, including upgrading its unique production platform, ExoPulse, and expanding partnerships to enable pan-market access to the platform and GMP clinical grade exosomes for faster access to clinical trials.
“By achieving this Series A funding in what remains a challenging time across the life science sector, EXO Biologics has received an endorsement from its founders, existing and new investors. This significant investment will support EXO Biologics in obtaining non-dilutive funding. It will also enable EXO Biologics to bring novel exosome therapies to patients with few alternative therapeutic options,” said Hugues Wallemacq, Chief Executive Officer (CEO) of EXO Biologics. “Having now launched the first clinical trial approved by the EMA to use MSC-based exosomes, EXO Biologics is now able to support the clinical development of these highly promising therapies globally. This significant funding will therefore enable EXO Biologics to accelerate development and commercial agreements with third parties worldwide.”
EXO Biologics initially raised EUR 9 million from investors, including Noshaq, Founders, and Belgian Family Offices. This support allowed EXO Biologics to add substantial additional funding in the form of subsidies from the Public Service of Wallonia (SPW) in Belgium, amounting up to a further EUR 7 million.
A significant portion (EUR 5.5 million) of the public subsidies has been granted via the Technological Innovation Partnership for Advanced Therapy Medicinal Products (ATMP-PIT) initiative. This three-year program has been launched by BioWin and the SPW under the Walloon Recovery Plan in Belgium. It involves 26 partners and will fuel collaborations between academia, research institutions, and businesses, driving forward the development and manufacturing of next-generation biomedicines.
EXO Biologics will direct the funding towards advancing transformative healthcare initiatives, including the enrolment in EVENEW, the first European Medicines Agency (EMA) authorized clinical t
Revatis
772 followers
1w
Exciting News! Collaboration Alert at Revatis!🔬
We are delighted to announce the expansion of the collaboration between #Trince and #Revatis, marking a significant milestone in our journey. Together, we are proud to introduce the first photoporation platform in Wallonia, developed as part of the Mitosir project under the "BioWin-ATMP collaborative project."
The Mitosir project is dedicated to tackling muscular mitochondrial dysfunction seen in sarcopenia, a significant health issue. For this purpose, we have joined forces with #Genflow, a distinguished industrial partner known for their expertise and intellectual property in Sirtuin peptides, which are essential for mitochondrial function and anti-aging.
We're confident this collaboration will propel research in the realm of muscle health, and we're proud to work in tandem with ULB and the Uliege to explore the fundamental aspects of this critical topic.
Keep an eye out for more thrilling updates on this project! 💪💡
#stemcells #cellgenetherapy #MuscleHealth #Research #Innovation #Revatis #Trince #Genflow #ULB #Uliege #Rise #Photoporation #MitochondrialDysfunction #Sarcopenia #Biowin #wallonierelance
...............
Revatis
772 followers
1d
A nice paper authored by Julien Duysens, our PhD student within the company, made possible through a grant from Wallonia.
Didier Serteyn
Professor Liege University
1d
Latest Development: In our pursuit of advancing tissue engineering and extra cellular Vesicles (exosomes) production, we're working towards a significant milestone. While our goal of harvesting 1 billion muscle derived MSCs (#revatis) from a single muscle microbiopsy (10 mg) at P3 is ambitious, we're making progress step by step.
Stay tuned for updates on our journey! #stemcells #tissueengineering #regenerativemedicine #cellandgenetherapy #equinehealth #exosomes #extracellularvesicles
"be the first to know about our groundbreaking advancements"......sounds encouraging!!! Gla ;-)
Interesting for Genflow to post the following on Linkedin a couple of hours after suspension. Gla -)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,594 followers
6h
Stay up-to-date with Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!
Sign up for our latest updates and be the first to know about our groundbreaking advancements. Don't miss important news & exclusive insights - subscribe now: hTtps://loom.ly/ViGV0h8
#GENF #GENFF #biotech #genetherapy #aging
It’s the phrase, “and other circumstances beyond its control” that is intriguing. Would seem to indicate there is a third party involved in some way.
Marmie
Hopefully so Northeast, but could be something and nothing, although not sure how many other listed companies would as ask for a suspension because the Audit process was taking longer than plannned, and so very intriguing Genflow confirmed "the delay is not related to the Company's cash flow or other underlying economic position". Very interesting and somewhat exciting as we await their next update....it would be amazing if some other party have their financial accounts under due diligence, hence the delay...just a thought. Gl :-)
What Is Due Diligence?
Due diligence is an investigation, audit, or review performed to confirm facts or details of a matter under consideration.
In the financial world, due diligence requires an examination of financial records before entering into a proposed transaction with another party.
Im sure whatever it is we will find out. Could be a number of blockbuster reasons
Lol Porter, stranger things have happened but I'm sure your realistic opinion on due diligence is correct, unless the due diligence is from a JV partner and or T/O approach, " and other unforeseen circumstances out of its control " is certainly intriguing. Hopefully shouldn't take too long before the re-listing when everything will be made clear. Gl :-)
I have just under 1% of the company float, so dare not dream about a buy out. I know the directors would not consider any petty sums for a takeover, especially with their current cash position, ability to attract European Union backed non dilutive grants, 2 patents pending, 4 core programmes in development, overarching protection from other awarded patents and billion dollar deals being agreed for early stage pharma companies.
I’m going to try remain hopeful but realistic that it’s just a due diligence exercise and good conduct on behalf of the company, or I might make myself sick with shock.
Every chance Northeast............Take over looming????? Gl -)
" due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control"
Big things happening here!
Excitement building , ust gone UP a notch!!! Gla ;-)
Genflow Biosciences Plc
Temporary Suspension of Listing pending publication of Annual Financial Report
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, provides the following update in relation to the publication of its Annual Financial Report ("Annual Report").
The Company was required to publish its Annual Report for the financial year ending 31 December 2023 by 30 April 2024. However, due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control, the Company requires a short amount of additional time. The delay is not related to the Company's cash flow or other underlying economic position.
As a result, at the Company's request, the listing of the Company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended with effect from 7.30 a.m. on 1 May 2024 pending publication of the Annual Report.
At least we can't lose the ground we've made over the last few days now.
Follow that with a good set of results and we could fly
The one post wonderings arrive
Lol what? The Audit isn't out in time that's all. This isn't getting taken over. It'll come back in a fortnight
Strong second RNS! Nothing to do with the financial position. That’s all that matters. Could be something big happening
Never seen it happen before but “at the request of the company” doesn’t sound so bad as a forced suspension. Hopefully, lol.
No idea. Hopefully something good. Takeover????
Any ideas why company have requested temporary suspension?!
More buys than sells although the 1m yesterday was timed at 4.35pm and so anyone's guess and the 1.5m sell was timed at 2.08pm yesterday, which was directly followed by 5 x 100k buys and 5 x 200k buys, and so obviously soaked up immediately or even could have been a Bed & ISA , whereby they couldn't execute in one hit because of the demand, and the reason the flurry of buys thereafter. Anyways, all in the mix regardless and no doubt given how the majority of shares are now very tightly held as the free float gets smaller, the demand for shares will continue and the sp will continue its upward momentum, in anticipation of great things to come. Gl :-)
Strange that the 1.5M sell didn’t make a dent. That sell and the 1M and another 500k yesterday has not impacted the sp.
M
Every chance Porter, and the $1 Billion deal announced last week is the most exciting and most interesting and relevant to Genflow, given their planned phase 1/11 clinical trial in NASH...R&D focussed on the liver is hot hot hot at the moment, and so would a Major Pharma wait for trial resultsor get in early on the back of stellar pre-clinical studies, which were expected end of 2023!!!??? .Gl :-)
UK biotech signs $1bn deal to develop liver disease drugs
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Ian Johnston 14 HOURS AGO
German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.
Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.
The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.
https://www.ft.com/content/3cd4fc3c-e52b-4042-9540-08ce2444b5bd
This article today alone, shows anything biopharma is hot stuff, with companies being snapped up for £billions.
https://www.biospace.com/article/biospace-mergers-and-acquisitions-tracker/